Integer Holdings Corp (NYSE:ITGR) has earned a consensus rating of “Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $68.07.

A number of analysts have weighed in on ITGR shares. ValuEngine lowered Virtu Financial from a “hold” rating to a “sell” rating in a report on Tuesday, June 18th. Zacks Investment Research lowered shares of GenMark Diagnostics from a “hold” rating to a “sell” rating in a research note on Wednesday, April 24th. Finally, Argus raised their price target on shares of Aqua America from $2.00 to $43.00 in a report on Wednesday, June 5th. They noted that the move was a valuation call.

NYSE ITGR traded down $0.47 on Friday, hitting $81.65. The company’s stock had a trading volume of 9,268 shares, compared to its average volume of 230,030. The firm has a market capitalization of $2.68 billion, a price-to-earnings ratio of 21.53 and a beta of 0.95. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.49 and a current ratio of 2.55. The firm’s 50-day simple moving average is $77.87. Integer has a 52-week low of $67.25 and a 52-week high of $92.61.

Integer (NYSE:ITGR) last issued its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.00 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.80 by $0.20. Integer had a return on equity of 13.37% and a net margin of 14.67%. The company had revenue of $314.70 million during the quarter, compared to analyst estimates of $302.29 million. During the same quarter in the previous year, the company posted $0.61 earnings per share. Integer’s revenue was up 7.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Integer will post 4.3 earnings per share for the current fiscal year.

In other news, Director James F. Hinrichs bought 3,750 shares of the company’s stock in a transaction dated Thursday, May 23rd. The shares were acquired at an average cost of $68.47 per share, with a total value of $256,762.50. Following the completion of the transaction, the director now directly owns 6,549 shares in the company, valued at approximately $448,410.03. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.24% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of ITGR. Optimum Investment Advisors acquired a new stake in Integer during the 1st quarter valued at $30,000. Robeco Institutional Asset Management B.V. bought a new stake in Integer during the first quarter worth $40,000. Financial Gravity Wealth Inc. purchased a new stake in Integer during the 1st quarter worth about $45,000. PNC Financial Services Group Inc. lifted its holdings in Integer by 15.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,065 shares of the medical equipment provider’s stock worth $81,000 after purchasing an additional 145 shares in the last quarter. Finally, Pearl River Capital LLC bought a new position in Integer in the 1st quarter worth about $120,000. Institutional investors and hedge funds own 96.00% of the company’s stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer worldwide. It operates in two segments, Medical and Non-Medical. The company offers products for vascular, cardiac surgery, and structural heart diseases; peripheral vascular, neurovascular, urology, and oncology products; and electrophysiology, infusion therapy, and hemodialysis products.

Featured Article: Catch-Up Contributions

Receive News & Ratings for Integer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integer and related companies with MarketBeat.com's FREE daily email newsletter.